CLINICAL PHARMACOLOGY REVIEW

NDA:	**22-307 N000**
Submission Dates:	**12/27 2007, 2/4 2/19 2/25, 2/28 3/20, 4/28, 5/9 5/12 2008**
Brand Name:	**Effient**
Generic Name:	**Prasugrel Hydrochloride**
Dosage Form & Strength:	Tablets 5 mg and 10 mg
Indication:	Reduction of atherothrombotic events and stent thrombosis in ACS patients with stable angina or NSTEMI
Applicant:	Eli Lilly, Inc.
Submission:	Original NDA
Divisions:	DPEI and Cardio-Renal Drug Products, HFD-110
Primary Reviewers:	Elena V. Mishina, Ph.D. Sripal Mada, Ph. D.
Team Leader:	Patrick Marroum, Ph.D.
Pharmacometrics Consult:	Raj Madabushi, Ph.D.
Pharmacometrics Team Leader:	Yaning Wang, Ph.D.
QT Consult:	Nitin Mehrotra, Ph. D.
QT Team Leader:	Christine Garnett, Ph. D.

Table of Contents

1 EXECUTIVE SUMMARY 16

1.1 RECOMMENDATIONS: 16
1.2 PHASE IV COMMINMENTS: 17
1.3 SUMMARY OF OCPB FINDINGS 18
1.3.1 Background 18
1.3.2 Current Submission 18

2 QUESTION BASED REVIEW 22

2.1 GENERAL ATTRIBUTES 22
2.2 GENERAL CLINICAL PHARMACOLOGY 23
2.3 INTRINSIC FACTORS 39
2.4 EXTRINSIC FACTORS 48
2.5 GENERAL BIOPHARMACEUTICS 50
2.6 ANALYTICAL SECTION 53

3 DETAILED LABELING RECOMMENDATIONS 55

4 APPENDIX II: 60

4.1 INDIVIDUAL IN VITRO STUDY REVIEWS 60
4.1.1 In Vitro Protein Binding of Metabolites OF CS-747 (Report No. ATR-151-053) 60
4.1.2 Exploratory Studies on the in Vitro Biotransformation of Prasugrel (LY640315) by Human Carboxylesterases 1 and 2 (Report # 2007IV-EI002) 63
4.1.3 Examination of Effects of LY640315 on CYP1A2 and CYP3A in Primary Cultures of Human Hepatocytes 65
4.1.4 In Vitro Interaction of LY640315 (CS-747) Metabolites R-95913, R-138727, and R-106583 with Human Cytochrome P450 CYP3A 67
4.1.5 In Vitro Interaction of LY640315 (CS-747) Metabolites R-95913, R-138727, and R-106583 with Human Cytochromes P450 CYP2D6, CYP2C9, CYP2C19, and CYP1A2 70
4.1.6 Identification of the Human Cytochromes P450 Responsible for the Formation of R-138727, the Active Metabolite of LY640315, from R-95913 74
4.1.7 Characterization of the Human Cytochromes P450 Responsible for the Formation of the Isomer Sets (RS/RR and SR/SS) of R-138727, the Active Metabolites of LY640315, from R-95913 78
4.2 INDIVIDUAL IN VIVO STUDY REVIEWS 82
4.2.1 ^{14}C-CS-747 (LY640315): Disposition after Oral Administration (H7T-LC-TAAB) 82
4.2.2 A Single Ascending Dose Tolerance Study of Cs-747 in Healthy Male Volunteers with Pharmacokinetic and Pharmacodynamic Assessment (S001) 93
4.2.3 A Double Blind, Placebo Controlled, Multiple Dose Study OF CS-747 Compared with Clopidogrel in Healthy Male Volunteers (S004) 99
4.2.4 A Study to Determine the Relative Bioavailability of 5 and 10 mg Prasugrel Tablets (Part A) and to Investigate the Pharmacokinetics of Prasugrel when Administered as a 5, 30 and 60 mg dose (Part B) in Healthy Subjects (TAAW) 103
4.2.5 Inhibition of platelet aggregation following loading and maintenance dose administration of 60/10 mg prasugrel, 300/75 mg and 600/75 mg clopidogrel in healthy subjects (H7T-EW-TAAZ) 110
4.2.6 Comparative Bioavailability Assessment of CS-747.base and CS-747.HCl with a Pilot CS-747.HCl Food Effect Assessment in Healthy Subjects (TAAF) 121
4.2.7 A Pharmacokinetics and pharmacodynamics of prasugrel metabolites after single and multiple dosing in subjects with liver disease and healthy subjects with normal hepatic function. (TAAN) 126
4.2.8 Pharmacokinetics and Pharmacodynamics of Prasugrel Metabolites after Multiple Dosing in Subjects with Moderate Liver Disease and Healthy Subjects with Normal Hepatic Function (TABV) 135
4.2.9 Pharmacokinetics and Pharmacodynamics of Prasugrel Metabolites After Single Doses of 5 to 60 mg in Subjects with Normal Renal Function and Subjects with End Stage Renal Disease on Haemodialysis (TACJ) 142

4.2.10 Pharmacokinetics of Prasugrel Metabolites in Subjects with Moderate Renal Impairment, Subjects with End Stage Renal Disease Requiring Haemodialysis and Healthy Subjects with Normal Renal Function (TABW) 149
4.2.11 A Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Prasugrel in Healthy Chinese, Japanese and Korean Subjects Compared with Healthy Caucasian Subjects. (TABZ)....155
4.2.12 A study to evaluate the safety and tolerability of prasugrel in healthy Chinese subjects, and to compare effects of prasugrel and clopidogrel in Chinese and Caucasian subjects (TAAQ)....167
4.2.13 The Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel Metabolites in Healthy Subjects (TACG)....175
4.2.14 A Study of the Effects of a Proton Pump Inhibitor (Lansoprazole) on the Single Loading Dose Pharmacokinetics and Pharmacodynamics of CS-747.HCl and Clopidogrel in Healthy Subjects (TAAI)....184
4.2.15 The Effect of Oral Ranitidine on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel Active Metabolites in Healthy Subjects (TABS)....189
4.2.16 Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel Metabolites in Healthy Subjects (H7T-EW-TAAK)....195
4.2.17 Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel Metabolites in Healthy Male Subjects (H7T-EW-TAAV)....204
4.2.18 Effect of Prasugrel on the Disposition of Digoxin in Healthy Subjects (H7T-EW-TAAX)....212
4.2.19 Effect of Prasugrel on the Pharmacodynamic Response of Unfractionated Heparin in Healthy Subjects (H7T-EW-TAAT)....216
4.2.20 Aspirin Interaction Study With Prasugrel or Clopidogrel in Healthy Subjects (H7T-EW-TAAE)..223
4.2.21 Assess the Pharmacodynamic Interaction between Aspirin and Prasugrel in Healthy Subjects (H7T-EW-TAAU)....227
4.2.22 Effect of Prasugrel on the Pharmacodynamics and Pharmacokinetics of Single Dose Warfarin in Healthy Subjects (H7T-EW-TAAR)....233
4.2.23 Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Prasugrel Metabolites and the Effect of Prasugrel on the Disposition of Bupropion in Healthy Male Subjects (H7T-EW-TAAS)....240

5 APPENDIX III: BIOPHARMACEUTICS....247

5.1 BIOPHARMACEUTICS....247
5.1.1 Relative Bioavailability of Stored Compared to Newly Manufactured Tablets after a 60 mg Prasugrel Loading Dose in Healthy Subjects....247
5.1.2 Relative Bioavailability of Stored Compared to Newly Manufactured Tablets after a 60 mg Prasugrel Loading Dose in Healthy Subjects taking a Proton Pump Inhibitor....251
5.1.3 The effect of Active Pharmaceutical Ingredient Surface Area on the Relative Bioavailability of a 60 mg Prasugrel Loading Dose in Healthy Subjects Taking a Proton Pump Inhibitor....256

6 APPENDIX IV: OCP FILING REVIEW FORM....261

7 APPENDIX V: PHARMACOMETRICS REVIEW....263

List of Tables

Table 1 The range for the time difference between loading dose and start of PCI 28
Table 2 Comparison of Hazard Ratios for Quartiles 31
Table 3 Pharmacokinetic Parameter Estimates for R-138727 35
Table 4. AUC values of R-138727 in Healthy Subjects and in Patients 35
Table 5. Comparison of the Pharmacokinetic Parameters of Prasugrel Metabolites 38
Table 6. Effect of Body Weight on AUC and Cmax of R-138727 40
Table 7 Summary of Formulations Used in Clinical Studies 51
Table 8. Fed vs Fasted PK Parameters for Prasugrel Metabolites 52
Table 9. Protein binding ratios of R-95913, R-100932, R-106583 and R-119251 in rat (left panel) and dog (right panel) plasma 61
Table 10 Protein binding ratios of R-95913, R-100932, R-106583 and R-119251 in human plasma 62
Table 11 Protein binding ratios of R-138727 in 4% HSA 62
Table 12. Effect of R-138727 In Vitro on the CYP3A Mediated Metabolism of Midazolam to 1'-Hydroxy Midazolam 68
Table 13. Effect of R-106583 In Vitro on the CYP3A Mediated Metabolism of Midazolam to 1'-Hydroxy Midazolam 68
Table 14. Effect of R-106583 In Vitro on the CYP3A Mediated Metabolism of Testosterone to 6ß-Hydroxy Testosterone 68
Table 15. Inhibition of CYP2D6, CYP2C9, and CYP2C19 Form- Selective Catalytic Activities In Vitro by R-95913 72
Table 16. Enzyme Kinetic Profiles for the Formation of R-138727 from R-95913 in Expressed CYPs 75
Table 17. Percent Inhibition of R-138727 Formation in the Presence of 2, 4, or 8 μL of Ascites Fluid Containing Monoclonal Antibodies to CYP2B6 75
Table 18. Percent Inhibition of R-138727 Formation in the Presence of Sulfaphenazole, Omeprazole, or Ketoconazole 76
Table 19. Enzyme Kinetic Profiles for the Formation of R-138727 by Expressed CYP3A4 and CYP3A5 Supersomes 76
Table 20. Enzyme Kinetic Profiles for the Formation of RS/RR and SR/SS R-138727 from R-95913 in Human Liver Microsomes 79
Table 21. Enzyme Kinetic Profiles for the Formation of RS/RR and SR/SS R-138727 from R-95913 in Expressed Supersomes™ 79
Table 22. Subject Demographics 83
Table 23: Assay Characteristics of Inactive Metabolites in Plasma 83
Table 24 Assay Characteristics of an Active Metabolite in Plasma 83
Table 25. Mean (±SEM) Cumulative Percentages of a Single 15-mg (100 μCi) Oral Dose of [^{14}C]CS-747 Excreted in Human Urine and Feces 84
Table 26. Mean Percentages Metabolites in Pooled 0-24 hours Human Urine 87
Table 27: Assay Characteristics of Inactive Metabolites in Plasma 94
Table 28. Pharmacokinetic Parameters of R-95913 94
Table 29. Pharmacokinetic Parameters of R106583 95
Table 30. Pharmacokinetic Parameters of R100932 95
Table 31. Results of the Regression analysis for All Analytes 96
Table 32: Assay Characteristics of Inactive Metabolites in Plasma 99

Table 33. AUC(0-t) and Cmax Values for the 3 Metabolites of CS-747 on Day 1 100
Table 34: Assay Characteristics of Inactive Metabolites in Plasma 104
Table 35 Assay Characteristics of an Active Metabolite in Plasma 104
Table 36. Noncompartmental Pharmacokinetic Parameter Estimates for R-138727 After Single Prasugrel Doses 106
Table 37. Noncompartmental Pharmacokinetic Parameter Estimates for R-95913 After Single Prasugrel Doses 106
Table 38. Noncompartmental Pharmacokinetic Parameter Estimates for R-119251 After Single Prasugrel Doses 106
Table 39. Noncompartmental Pharmacokinetic Parameter Estimates for R-106583 After Single Prasugrel Doses 107
Table 40. Statistical Analysis of Relative Bioavailability between 2x5 mg and 1x10 mg Prasugrel Tablets (Part A) 107
Table 41. Statistical Comparison of tmax between 2x5 mg and 1x10 mg Prasugrel Tablets (Part A) 108
Table 42. Dose Proportionality Analysis between 5, 10, 30, and 60 mg Prasugrel (Parts A and B) 108
Table 43. Assay Characteristics of the active metabolites of Prasugrel and Clopidogrel 111
Table 44. Pharmacokinetic Parameter Estimates for R-130964 and R-138727 Following a Single LD and the Seventh MD of Clopidogrel and Prasugrel 112
Table 45. Dose Proportionality for the Pharmacokinetic Parameter of R-130964 Following a Single LD and the Seventh MD of Clopidogrel 113
Table 46: Assay Characteristics of Inactive Metabolites in Plasma 122
Table 47 Assay Characteristics of an Active Metabolite in Plasma 122
Table 48. Demographic Characteristics 122
Table 49 Formulation comparison between 15 mg CS-747.base (Fasted) vs. 15 mg CS-747.HCl (Fasted) 124
Table 50. Food effect comparison between 15 mg CS-747.HCl (Fed) vs 15 mg CS-747.HCl (Fasted) 124
Table 51. Assay Characteristics of Inactive Metabolites in Plasma 127
Table 52. Assay Characteristics of an Active Metabolite in Plasma 127
Table 53. Subject Demographics 128
Table 54. R-138727 130
Table 55. R-95913 130
Table 56. R-119251 131
Table 57. R-106583 131
Table 58. R-119251 132
Table 59. R-106583 132
Table 60. Mean (±SD) MPA to 20 μM ADP Following a 60-mg LD and the Fifth Daily 10-mg MD of Prasugrel in Subjects with Mild and Moderate Hepatic Impairment (Parts 1 to 3) and Healthy Subjects 134
Table 61. Assay Characteristics of Inactive Metabolites in Plasma 136
Table 62. Assay Characteristics of an Active Metabolite in Plasma 136
Table 63. PK Parameters in healthy subjects and in subjects with moderate hepatic impairment. 137

Table 64. Statistical Comparison of R-138727 Pharmacokinetic Parameters Between Subjects with Moderate Hepatic Impairment and Healthy Subjects After a 60-mg LD and After the Fifth Daily 10-mg MD of Prasugrel 138
Table 65. Statistical Comparison of R-95913, R-119251 and R-106583 Pharmacokinetic Parameters Between Subjects with Moderate Hepatic Impairment and Healthy Subjects Following a 60-mg LD and Fifth Daily 10-mg MD of Prasugrel 139
Table 66. Statistical Comparison of MPA to 20 μM ADP Between Subjects with Moderate Hepatic Impairment and Healthy Subjects After a 60-mg LD and After the Fifth Daily 10-mg MD of Prasugrel 140
Table 67. Assay Characteristics of Inactive Metabolites in Plasma 143
Table 68. Assay Characteristics of an Active Metabolite in Plasma 143
Table 69 Noncompartmental Pharmacokinetic Parameter Estimates for R-138727 after a Single 5-, 10-, 30- or 60-mg Prasugrel Dose in Healthy Subjects and ESRD Subjects 145
Table 70 Statistical Analysis of Pharmacokinetic Parameters for R-138727 after a Single 5-, 10-, 30- or 60-mg Prasugrel Dose in Healthy Subjects and ESRD Subjects 145
Table 71. PK Parameter Estimates for R-138727 151
Table 72. Statistical Analysis of Pharmacokinetic Parameters for R-138727 152
Table 73. Summary of Geometric Mean (CV%) Pharmacokinetic Parameters of R-138727 following a 60-mg LD of Prasugrel on Day 1 158
Table 74. Statistical Comparison of Prasugrel Active Metabolite (R-138727) Pharmacokinetic Parameters Between Chinese, Japanese, Korean, and Caucasian Subjects Following a 60-mg LD of Prasugrel on Day 1 158
Table 75. Statistical Comparison of R-95913, R-106583, and R-119251 Pharmacokinetic Parameters Between Chinese, Japanese, Korean, and Caucasian Subjects Following a 60-mg LD of Prasugrel on Day 1 159
Table 76. Summary of Geometric Mean (CV%) Pharmacokinetic Parameters of R-138727 Following 10-mg MDs of Prasugrel on Day 8 160
Table 77. Statistical Comparison of R-138727 AUC(0-tlast) Between Chinese, Japanese, Korean, and Caucasian Subjects Following 10-mg MDs of Prasugrel on Day 8 161
Table 78. Statistical Comparison of Prasugrel Inactive Metabolite AUC(0-tlast) Between Chinese, Japanese, Korean and Caucasian Subjects Following 10-mg MDs of Prasugrel on Day 8 161
Table 79 Summary of Geometric Mean (CV%) Pharmacokinetic Parameters of R-138727 Following 5-mg MDs of Prasugrel on Day 18 163
Table 80. Statistical Comparison of Prasugrel Active Metabolite (R-138727) AUC(0-tlast) Between Chinese, Japanese, Korean and Caucasian Subjects following 5-mg MDs of Prasugrel on Day 18 163
Table 81. Pharmacokinetic Parameter Estimates [Geometric Mean (%CV)] for Prasugrel Active Metabolite (R-138727) after Single Prasugrel Doses of 10, 20, 40 and 60 mg in Chinese Subjects (Parts A and B) 169
Table 82. Pharmacokinetic Parameter Estimates for Prasugrel Active Metabolite after a Single 60-mg Prasugrel Dose in Chinese and Caucasian Subjects 170
Table 83. Statistical Comparison of Prasugrel Metabolite Pharmacokinetic Parameters in Chinese and Caucasian Subjects after a Single 60-mg Prasugrel Dose 170
Table 84. Geometric Mean (CV%) Clopidogrel Active Metabolite Pharmacokinetic Parameters after a Single 300-mg Dose between Chinese and Caucasian Subjects 171

Table 85. Geometric Mean (CV%) Bleeding Time (s) Following Administration of Single Doses of Prasugrel and Placebo in Chinese Subjects (Parts A and B) 172
Table 86 Assay Characteristics of R138727 in Plasma 176
Table 87. Assay Characteristics of Inactive Metabolites in Plasma 176
Table 88. PK Parameters of R-138727 178
Table 89. Effect of Age on PK of R-138727 178
Table 90. Statistical Comparison of Pre- and Post-Aspirin Baseline MPA to 20 μM ADP in Healthy Young Subjects and Elderly Subjects 179
Table 91. Statistical Comparison of Baseline MPA to 20 μM ADP between Healthy Young Subjects and Elderly Subjects 179
Table 92. Statistical Comparison of MPA to 20 μM ADP between Healthy Young Subjects and Elderly Subjects Following 5 mg Prasugrel MDs and 10 mg Prasugrel MDs 180
Table 93. Statistical Comparison of VN-P2Y12 % Inhibition Between Healthy Elderly Subjects and Young Subjects Following 5 mg Prasugrel MDs and 10 mg Prasugrel MDs 181
Table 94. Statistical Comparison of Bleeding Time Ratios between Healthy Elderly Subjects and Young Subjects Following the Tenth Daily 5 mg Prasugrel MDs and the Tenth Daily 10 mg Prasugrel MDs 182
Table 95. Subject Demographics 185
Table 96. Effect of Lansoprazole (PPI) on the Pharmacokinetics of CS-747 Metabolites following Oral Administration of 60 mg CS-747.HCl 186
Table 97. Effect of Lansoprazole (PPI) on the Pharmacokinetics of the Inactive Metabolite S26334 following Oral Adminstration of 300 mg Clopidogrel 186
Table 98. Effect of lanzoprazole on IPA to 20 mcM ADP point estimate and 90%CI for mean IPA for four treatments 187
Table 99. Assay Characteristics of R138727 190
Table 100. Assay Characteristics of R361015 190
Table 101. PK Parameters of R138727 192
Table 102. PK Parameters of R130964 192
Table 103 Statistical Comparison of IPA (%) to 20 μM ADP Following LD of Prasugrel and Clopidogrel alone and with Ranitidine (Day 1) 193
Table 104. Statistical Comparison of IPA (%) to 20 μM ADP Following MD of Prasugrel and Clopidogrel alone and with Ranitidine (Day 8) 194
Table 105 Summary of subject demographics 197
Table 106 Method validation data using LCMS assay. 197
Table 107 Pharmacokinetic parameters for R-138727 and R-130964 after prasugrel or clopidogrel dosing without or with steady-state ketoconazole 200
Table 108 Validation parameters for plasma metabolites of prasugrel and clopidogrel. 206
Table 109 Noncompartmental Pharmacokinetic Parameter Estimates for R-138727 after a Single 60-mg Loading Dose and After the 10th Daily 10-mg Maintenance Dose of Prasugrel Alone and with Atorvastatin 208
Table 110 Statistical Analysis of the Effects of Atorvastatin on R-138727 Following 60-mg Prasugrel LD. 208
Table 111 Statistical Analysis of the Effects of Atorvastatin on R-138727 after the Tenth Daily 10-mg Prasugrel MD 208
Table 112 Statistical Analysis of the Effects of Atorvastatin on R-130964 After a 300-mg Clopidogrel Loading Dose 209

Table 113 Statistical Analysis of the Effects of Atorvastatin on R-130964 after the Tenth Daily 75-mg Clopidogrel Maintenance Dose. 209
Table 114 Statistical Comparison of IPA Response to 20 μM ADP Following Administration of Prasugrel Alone and with Atorvastatin. 210
Table 115 Summary of subject demographics 213
Table 116 Method validations (Intra day) for serum and urinary digoxin using LC/MS assay. 213
Table 117 Noncompartmental pharmacokinetic parameters for all treatment arms. 214
Table 118 Statistical comparisons of pharmacokinetics following digoxin administration in the presence of prasugrel. 215
Table 119 Subject Demographics. 217
Table 120 Statistical comparisons of individual APTT and ACT measurements between prasugrel 2 hours postdose (before UFH / saline dose) and placebo. 219
Table 121 Distribution of APTT values above the 240 seconds upper limit of quantification. . 219
Table 122 Statistical analysis for the coagulation parameters following UFH administration in the presence of prasugrel. 221
Table 123 Statistical comparisons of IPA response to 20 μM ADP following UFH administration in the presence of prasugrel. 222
Table 124 Statistical comparisons of bleeding time ratio following UFH administration in the presence of prasugrel. 222
Table 125 Subject Demographics 229
Table 126 Statistical comparisons of IPA response to 20 μM ADP following prasugrel administration in the presence of aspirin. 230
Table 127 Statistical comparisons of IPA response to 20 μM ADP following a single acute 900-mg dose of aspirin. 230
Table 128 Statistical comparisons of VASP phosphorylation following prasugrel administration in the presence of aspirin. 231
Table 129 Statistical comparisons of bleeding time ratio following prasugrel administration in the presence of aspirin. 232
Table 130 Statistical comparisons of bleeding time ratio following a single acute 900-mg dose of aspirin. 232
Table 131 Summary of subject demographics. 235
Table 132 Noncompartmental pharmacokinetics of R- and S-warfarin following warfarin administration in the presence of prasugrel. 237
Table 133 Statistical comparison of IPA to 20 μM ADP following warfarin administration in the presence of prasugrel 238
Table 134 Statistical comparison of bleeding time ratios following warfarin administration in the presence of prasugrel 239
Table 135 Statistical Comparison of Bleeding Time Ratio following prasugrel administration in the presence of warfarin. 239
Table 136 Method validation data using LCMS assay 241
Table 137 Noncompartmental Pharmacokinetic Parameter Estimates for Bupropion and Hydroxybupropion Following a Single 150-mg Dose of Bupropion Alone or with Prasugrel 243
Table 138 Noncompartmental Pharmacokinetic Parameter Estimates for R-138727 Following a Single 60-mg LD and After the Fifth Once Daily 10-mg MD of Prasugrel Alone and with Rifampicin. 245

Table 139 Results of Statistical Analysis of Rifampicin's Effects on Pharmacokinetic Parameters Estimates of Prasugrel Metabolites..... 245
Table 140 Statistical Comparison of IPA (%) to 20 μM ADP Following Administration of Prasugrel Alone and with Rifampicin..... 246